argenex (NASDAQ:ARGX) Stock Price Expected to Rise, Piper Sandler Analyst Says

argenex (NASDAQ:ARGX – Get Free Report) had its target price upped by equities research analysts at Piper Sandler from $1,215.00 to $1,350.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler‘s target price indicates a potential upside of 40.62% from the company’s current price.

Several other brokerages also recently issued reports on ARGX. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research report on Wednesday, October 21st. Oppenheimer reduced their target price on shares of argenex from $1,100.00 to $1,038.00 and set an “outperform” rating on the stock in a research report on Monday, October 12th. Citizens Jmp boosted their target price on shares of argenex from $932.00 to $1,200.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 18th. Wedbush decreased their target price on shares of argenex from $1,150.00 to $1,130.00 and set an “outperform” rating for the company in a research note on Thursday, October 8th. Finally, Deutsche Bank reissued a “neutral” rating on shares of argenex in a report on Friday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, argenex has a consensus rating of “Moderate Buy” and an average target price of $1,163.18.

Read Our Latest Research Report on argenex

argenex Stock Performance

Shares of NASDAQ:ARGX opened at $960.04 on Monday. The company has a market cap of $60.38 billion, a P/E ratio of 33.50, a PEG ratio of 0.89 and a beta of 0.48. argenex has a one year low of $661.85 and a one year high of $1,072.75. The business’s 50-day simple moving average is $923.87 and its 200 day simple moving average is $860.78.

argenex (NASDAQ:ARGX – Get Free Report) last released its quarterly earnings results on Friday, October 23rd. The company reported $7.80 EPS for the quarter, topping the consensus estimate of $7.44 by $0.36. The firm had revenue of $1.75 billion for the quarter. argenex had a return on equity of 47.70% and a net margin of 31.66%. Analysts predict that argenex will post 28.41 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Eastern Bank acquired a new position in shares of argenex in the 2nd quarter worth approximately $32,000. Harbour Investments Inc. increased its holdings in shares of argenex by 966.7% in the 3rd quarter. Harbour Investments Inc. now owns 64 shares of the company’s stock valued at $62,000 after acquiring an additional 58 shares during the last quarter. Axiom Investment Management LLC bought a new stake in shares of argenex in the 1st quarter valued at approximately $50,000. Richardson Financial Services Inc. acquired a new stake in shares of argenex during the 3rd quarter valued at approximately $66,000. Finally, Bogart Wealth LLC raised its position in shares of argenex by 2,500.0% during the 3rd quarter. Bogart Wealth LLC now owns 78 shares of the company’s stock valued at $75,000 after acquiring an additional 75 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

About argenex

(Get Free Report)

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.

Featured Stories

Analyst Recommendations for argenex (NASDAQ:ARGX)

Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.